# Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease

> **NCT01835496** · PHASE1 · COMPLETED · sponsor: **ApoPharma** · enrollment: 8 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** single 1500 mg dose of Ferriprox

## Key facts

- **NCT ID:** NCT01835496
- **Lead sponsor:** ApoPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01835496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01835496, "Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01835496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*